Endocrine Regulation of Lipolysis in Obesity and Diabetes

NCT ID: NCT02598544

Last Updated: 2016-11-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2015-04-30

Brief Summary

Adipose tissue (AT) dysfunction is a commonly observed feature of metabolic dysfunction in obesity and diabetes. An important characteristic when examining AT function is the capacity to break down stored lipids (i.e. lipolysis) and its regulation. In the present study, the aim was to investigate whether atrial natriuretic peptide-mediated lipolysis is altered in different adipose tissue depots (subcutaneous and visceral adipose tissue) of obese subjects with or without type 2 diabetes, compared to age-matched lean men. Eventually, the knowledge gained from this research will contribute to a better understanding of the present adipose tissue dysfunction and to the optimization of exercise programs for people with obesity and diabetes.

Conditions

Obesity; Diabetes

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: NONE

Study Groups

lean men

Group Type: OTHER

adipose tissue sampling

Intervention Type: OTHER

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Obese men without type 2 diabetes

Group Type: OTHER

adipose tissue sampling

Intervention Type: OTHER

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Obese men with type 2 diabetes

Group Type: OTHER

adipose tissue sampling

Intervention Type: OTHER

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Interventions

adipose tissue sampling

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Lean group: BMI < 25 kg/m², insulin sensitive (HOMA-Insuline Resistance (IR) < 2.3), age 40-65
• Obese groups: BMI > 30 kg/m², presence or absence of type 2 diabetes based on use of glucose lowering medication or HbA1c > 6.5%, age 40-65

Exclusion Criteria

• presence of a history of heart, lung or kidney disease and/or presence of endocrine anomalies. Use of beta-blockade medication.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Jessa Hospital

OTHER

Sponsor Role: collaborator

Hasselt University

OTHER

Sponsor Role: lead

Responsible Party

Dominique Hansen

prof. dr.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dominique Hansen, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

Hasselt University

Ellen Blaak, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

Maastricht University

Kenneth Verboven, drs.

Role: STUDY_CHAIR

Hasselt University

Locations

Hasselt University

Diepenbeek, , Belgium

Ziekenhuis Oost-Limburg

Genk, , Belgium

Jessa Ziekenhuis

Hasselt, , Belgium

Maastricht University

Maastricht, , Netherlands

Countries

Belgium; Netherlands

Other Identifiers

14.17/REVA14.02

Identifier Type: -

Identifier Source: org_study_id